ClinicalTrials.gg
Active, not recruitingNCT04739761DESTINY-B12Updated Nov 12, 2026Results posted

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

A Phase 3 interventional study of Trastuzumab Deruxtecan in Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 81 sites in 18 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
8th of 58
506 · median 139
Started
2021
with 2 others
Phase 3
12 of 58
3 open now
Primary completion
2024-02
later than 1 of 44 live
Registered
18th of 58
by date
Lead sponsor
9 of 58
AstraZeneca

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 3 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 1 of the 44 other live ones, and was the 18th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).

Read the detailed description

Approximately 500 eligible participants will be enrolled into 1 of 2 cohorts (250 participants in each cohort) according to the presence or absence of BMs at baseline. Cohort 1 will include participants without BM at baseline and Cohort 2 will consist of participants with BM at baseline.

After study intervention discontinuation, all participants will undergo an end-of-treatment visit (within 7 days of discontinuation) and will be followed up for safety assessments 40 (+ up to 7) days after the discontinuation of all study intervention.

All participants will be followed up for survival status and duration of treatment on subsequent therapies after intervention discontinuation every 3 months (± 14 days) from the date of the safety follow-up until death, withdrawal of consent, or the end of the study, as per defined in the protocol.

03

Conditions studied

  • Breast Cancer

Keywords

  • Trastuzumab deruxtecan
  • Human epidermal growth factor receptor 2 Positive Breast Cancer
  • Brain Metastasis
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants should have documented breast cancer that is: unresectable/advanced or ; confirmed -positive status expression as determined according to American Society of Clinical Oncology/College of American Pathologists guidelines
  • Participant must have either: no evidence of BM, or untreated BM on screening contrast brain magnetic resonance imaging/ computed tomography (MRI/CT) scan, not needing immediate local therapy or previously-treated stable or progressing BM
  • Participants with BMs must be neurologically stable
  • For participants requiring radiotherapy due to BMs, there should be an adequate before day of first dosing:
  • ≥ 7 days since stereotactic radiosurgery or gamma knife
  • ≥ 21 days since whole brain radiotherapy
  • performance status 0-1
  • Previous breast cancer treatment: radiologic or objective evidence of disease progression on or after HER2 targeted therapies and no more than 2 lines/regimens of therapy in the metastatic setting
  • Participant with the following measurable: at least 1 lesion that can be accurately measured at baseline as ≥ 10 mm in the longest diameter with CT or MRI and is suitable for accurate repeated measurements; or following Non-measurable diseases: Non-measurable, bone-only disease that can be assessed by CT or MRI or X-Ray. Lytic or mixed lytic bone lesions that can be assessed by CT or MRI or X-ray in the absence of as defined above is acceptable; Participants with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible; and Non-measurable CNS disease (Cohort 2 only)
  • Adequate organ and bone marrow function within 14 days before the day of first dosing as defined in the protocol
  • ≥ 50% within 28 days before enrollment
  • Negative pregnancy test (serum) for women of

Exclusion criteria

Exclusion Criteria

  • Known or suspected
  • Prior exposure to tucatinib treatment
  • nausea and vomiting, chronic gastrointestinal disease, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of T-DXd
  • History of another primary except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence
  • Based on screening contrast brain MRI/CT scan, participants must not have any of the following: any untreated brain lesions > 2.0 cm in size; ongoing use of systemic for control of symptoms of BMs; any brain lesion thought to require immediate local therapy; have poorly controlled (> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to BMs not withstanding CNS-directed therapy
  • Has spinal cord compression
  • Known active or C infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1 Day 1. Participants with past or resolved hepatitis B virus infection are eligible, if negative for hepatitis B surface antigen and positive for anti-hepatitis B core antigen
  • Participants positive for virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
  • Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • Receipt of live, attenuated vaccine within 30 days prior to the first dose of T-DXd
  • Participants with a medical history of myocardial infarction within 6 months before screening, symptomatic congestive heart failure ( Class II to IV)
  • History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  • Lung-specific intercurrent illnesses and any , connective tissue or inflammatory disorders
  • Prior exposure, without adequate treatment before the day of first dosing, to chloroquine/hydroxychloroquine: \< 14 days
  • Anticancer chemotherapy: immunotherapy (non-antibody-based therapy), retinoid therapy, hormonal therapy: \< 3 weeks
  • \< 6 weeks for nitrosoureas or mitomycin
  • Antibody-based anticancer therapy: \< 4 weeks
  • Any concurrent anticancer treatment. Concurrent use of hormonal therapy for noncancer- related conditions is allowed
  • Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline
  • Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation, radiation to the chest, or to more than 30% of the bone marrow within 4 weeks before the first dose of study intervention
  • Participants with prior exposure to medication within 14 days prior to first study dose
  • Participants with a known to study intervention or any of the of the product or other monoclonal antibodies
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
506 participants (actual)

Study arms

  • Experimental
    Trastuzumab Deruxtecan

    Participants with or without BM at baseline will receive intravenous (IV) T-DXd, 5.4 mg/kg, every 3 weeks (21-day cycle) until Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined radiological progression outside central nervous system, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.

    Drug: Trastuzumab Deruxtecan

Interventions

  • Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.

    Also known as: fam-trastuzumab deruxtecan-nxki

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)

    The ORR is defined as the percentage (%) of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by independent central review (ICR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    Time frame: From first dose (Day 1) to progression of disease (up to 2 years 7 months)

  2. Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)

    The PFS rate is the percentage of participants alive and free of disease progression at 12 months, estimated by the Kaplan-Meier method.

    Time frame: At 12 months

Secondary outcomes

  1. Survival Rate at 12 Months

    Survival rate is the percentage of participants alive at 12 months, estimated by the Kaplan-Meier method.

    Time frame: At 12 Months

  2. Objective Response Rate in Cohort 2 (Participants With Brain Metastasis at Baseline)

    The ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.

    Time frame: From first dose (Day 1) to progression of disease (up to 2 years 7 months)

  3. Duration of Response (DoR)

    Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 as assessed by ICR or death due to any cause.

    Time frame: From the date of first documented confirmed response until date of documented progression (up to 2 years 7 months)

  4. Time to Progression

    Time to progression by RECIST 1.1 per ICR is defined as the time from the date of the first dose of study intervention to the date of documented disease progression.

    Time frame: From first dose (Day 1) to progression of disease (up to 2 years 7 months)

  5. Duration of Treatment on Subsequent Lines of Therapy

    Duration of treatment on subsequent therapy is defined as the time from the date of first dose of a subsequent therapy until date of the last dose of that therapy.

    Time frame: From the date of first dose of a subsequent therapy until date of last dose of therapy (up to 2 years 7 months)

  6. Second Progression-Free Survival Rate at 12 Months

    Second progression-free survival rate is the percentage of participants alive and free from a second progression on next-line treatment at 12 months, estimated by the Kaplan-Meier method. The second progression is defined as the earliest progression event subsequent to the first anti-cancer therapy after the initial progression.

    Time frame: At 12 Months

  7. Incidence of New Symptomatic Central Nervous System (CNS) Metastasis During Treatment Without CNS Metastasis at Baseline (Cohort 1)

    The incidence rate is defined as proportion of participants with new symptomatic CNS metastases during treatment period in participants without symptomatic CNS metastasis at baseline.

    Time frame: From first dose (Day 1) to end of treatment (up to 2 years 7 months)

  8. Time to Next Progression (CNS or Extracranial) or Death

    The time to next progression is defined as the time from the date of the first documented isolated CNS progression to the date of the next documented disease progression (CNS or extracranial) per RECIST 1.1 or death and has been summarized descriptively in participants who have developed isolated CNS progression, receive local therapy, and continue on protocol therapy.

    Time frame: From date of first documented isolated CNS progression to the date of the next documented disease progression (up to 2 years 7 months)

  9. Site (CNS vs Extracranial vs Both) of Next Progression

    Site of next progression (CNS \[CNS RECIST 1.1\] or extracranial \[systemic RECIST 1.1\] in participants who developed isolated CNS progression, received local therapy, and continued on protocol therapy.

    Time frame: From the date of the first documented isolated CNS progression to the date of the next documented CNS disease progression (up to 2 years 7 months)

  10. Central Nervous System Progression-free Survival Rate at 12 Months in Participants With Brain Metastasis at Baseline (Cohort 2)

    Central nervous system progression free survival rate is the percentage of participants free from central nervous system progression at 12 months, estimated by the Kaplan-Meier method.

    Time frame: At 12 Months

  11. Time to New CNS Lesions in Participants With Brain Metastasis at Baseline (Cohort 2)

    The time to new CNS lesions is defined as the time from the date of the first dose of study intervention to the date of documented new CNS lesions by RECIST 1.1 per ICR.

    Time frame: From first dose (Day 1) to the date of documented new CNS lesions (up to 2 years 7 months)

  12. Central Nervous System Objective Response Rate in Participants With Brain Metastasis at Baseline by ICR (Cohort 2)

    The CNS ORR is defined as the percentage of participants with measurable brain metastasis at baseline who have a confirmed CR or confirmed PR of brain lesions, as determined by ICR per CNS RECIST 1.1.

    Time frame: From first dose (Day 1) until CNS progression of disease (up to 2 years 7 months)

  13. Central Nervous System Duration of Response in Participants With Brain Metastasis at Baseline (Cohort 2)

    The CNS DoR is defined as the time from the date of first documented confirmed CNS response until date of documented CNS progression per CNS RECIST 1.1 as assessed by ICR or death due to any cause.

    Time frame: From date of first documented confirmed CNS response until CNS progression of disease (up to 2 years 7 months)

  14. Number of Participants With Best on Treatment Visit Response on the European Organization for the Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a 30-item questionnaire for cancer assessment. Increased scores indicate improvement; decreased scores indicate deterioration. Physical function: ≥+9= improvement, ≤-10=deterioration, otherwise=no change; Role functioning: ≤-6=deterioration, otherwise=no change; Social functioning: ≥+8=improvement, ≤-7=deterioration, otherwise=no change; Cognitive functioning: ≥+ 5=improvement, ≤- 4=deterioration, otherwise=no change; Global Health Status: ≥+2=improvement, ≤-8=deterioration, otherwise=no change; Fatigue: ≥+8=improvement, ≤-8=deterioration, otherwise=no change; Nausea and vomiting: ≤-11=deterioration, otherwise=no change; Appetite loss: ≤-14=deterioration, otherwise=no change; rest of scales: ≥+10=improvement, ≤-10=deterioration, otherwise=no change. Best on treatment response is best response category (improvement, no change, and deterioration) achieved by participants between first dose and 47 days after last dose, and prior to starting any anticancer therapy.

    Time frame: Time from first dose up to 47 days after last dose, or prior to starting any subsequent therapy, or for up to 2 years 7 months, whichever occurred first

  15. Number of Participants With Neurologic Assessment in Neuro-Oncology Scale (NANO Scale)

    The NANO scale is a clinician-reported assessment of neurologic functioning in neuro-oncology participants. The instrument captures 9 domains (gait, strength, ataxia, sensation, visual fields, facial strength, language, level of consciousness, and behavior) and was developed to provide a simple, objective assessment of neurologic function that would be combined with radiographic assessment to provide an overall outcome assessment for neuro-oncology participants in clinical trials and in daily practice. The soring scale for Gait consists of score range 0-3, Strength consists of score range 0-2, ataxia (upper extremity) consists of scale range 0-2 and sensation as 0. Higher scores indicate worse neurologic function. The response categories reported are changes from first post-baseline score to worst on-treatment score at any point of treatment.

    Time frame: Time from first dose up to 47 days after last dose, or prior to starting any subsequent therapy, or for up to 2 years 7 months, whichever occurred first

  16. Cognitive Functions Tests: Paired Associates Learning (PAL) First Attempt Memory Score (PALFAMS)

    The PAL is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included PAL and was a low-burden, highly sensitive, precise measure of cognitive function. The PALFAMS is the number of times a participant chose the correct box on their first attempt when recalling the pattern locations, calculated across all assessed trials. A higher number of events of selecting correct boxes indicates better cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

    Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)

  17. Cognitive Functions Tests: Paired Associates Learning Total Errors Adjusted (PALTEA)

    The PAL is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included PALTEA and was a low-burden, highly sensitive, precise measure of cognitive function. PALTEA is the number of times a participant chose the incorrect box for a stimulus on assessment problems, plus an adjustment for the estimated number of errors they would have made on any problems, attempts, and recalls they did not reach. A higher number of events of selecting incorrect boxes indicates worse cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

    Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)

  18. Cognitive Functions Tests: Reaction Time (RTI)

    This is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included Reaction Time Task (RTI) and was low-burden, highly sensitive, precise measures of cognitive function. RTI Median Five-Choice Movement Time: median time taken for a participant to release response button and select target stimulus after it flashed yellow on screen. Calculated across correct, assessed trials in which stimulus could appear in any one of five locations. RTI Median Five-Choice Reaction Time: median duration it took for a participant to release response button after presentation of target stimulus. Calculated across correct, assessed trials in which stimulus could appear in any one of five locations. Measured in milliseconds. Higher reaction times indicate worse cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

    Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)

  19. Cognitive Functions Tests: Spatial Working Memory (SWM)

    The SWM is a computerized cognitive test. The SWM Between Errors (SWMBE) is number of times a participant incorrectly revisits a box in which a token has previously been found, calculated across all 4, 6, and 8 token trials. SWM Between Errors 4 Boxes (SWMBE4), SWM Between Errors 6 Boxes (SWMBE6), and SWM Between Errors 8 Boxes (SWMBE8) are number of times a participant revisits a box in which a token has previously been found. These are calculated across all trials with 4 tokens only for SWMBE4, 6 tokens only for SWMBE6, and 8 tokens only for SWMBE8. SWM Total Errors is number of times a box is selected that is certain not to contain a token and therefore should not have been visited by participant. A higher number of incorrect revisit events to previously found token boxes indicates worse cognitive function, and a lower number of revisit events indicates better cognitive function. Here, baseline was last non-missing value prior to administration of first dose of study intervention.

    Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)

  20. Cognitive Functions Tests: Spatial Working Memory Strategy (SWMS)

    The SWM is a computerized cognitive test. The SWMS, the number of times a participant restarted search patterns from the same initial box, indicating their use of a planned strategy to find tokens. An increased number of events where search patterns started from the same initial box suggested participants were using a planned strategy to find tokens, which indicated better cognitive function. Here, a low score indicated high strategy use (1 = they always began the search from the same box). Conversely, high scores represented a decrease in events of beginning searches from the same box. Instead, starting from many different boxes suggested the participant was not using a consistent strategy, which indicated worse cognitive function. This was calculated across assessed trials with 6 tokens or more. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

    Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)

  21. St. George's Respiratory Questionnaire - Idiopathic (SGRQ-I) Pulmonary Fibrosis Version in Participants With Interstitial Lung Disease (ILD)/Pneumonitis

    The effect of T-DXd on symptoms, functioning, and HRQoL in HER2+ MBC participants with or without baseline brain metastasis was evaluated. The SGRQ-I is an idiopathic pulmonary fibrosis-specific version of the instrument developed and validated for use among participants with idiopathic pulmonary fibrosis, a type of ILD. The SGRQ-I was used to assess the HRQoL among participants who have been diagnosed with ILD/pneumonitis. It includes 34 of the original SGRQ items determined to be most reliable for assessing the HRQoL of participants with idiopathic pulmonary fibrosis. The instrument yields 3 domain scores (symptoms, activity, and impact) as well as a total score, with scores ranging from 0 to 100. Higher scores indicate greater impairment in HRQoL.

    Time frame: From time of ILD/pneumonitis diagnosis (every week) until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)

  22. MD Anderson Symptom Inventory Brain Tumor-Specific Items in Brain Metastasis at Baseline Participants

    The T-DXd on symptoms, functioning, and HRQoL in HER2+ MBC participants with or without baseline brain metastasis was evaluated. The MDASI brain tumor module includes 9 symptoms specific to brain tumors (weakness on one side of the body, difficulty understanding, difficulty speaking, seizures, difficulty concentrating, problems with vision, change in appearance, change in bowel pattern (diarrhea or constipation), and irritability). These 9 items will be used to capture symptoms associated with brain metastasis for those diagnosed with brain metastasis. Each item is rated on an 11-point numeric rating scale on a scale of 0-10, with higher scores indicating greater symptom severity. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

    Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, and Cycle 39 Day 1 (21 days cycle)

  23. Number of Participants With Adverse Events (AEs)

    The safety and tolerability of the participants who received T-DXd was evaluated. SAE=Serious adverse events; CTCAE=Common Terminology for Adverse Events

    Time frame: From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)

  24. Number of Participants With Investigator-assessed ILD/Pneumonitis

    The number of participants with ILD/Pneumonitis were by grouped term based on Investigator-reported preferred terms. No adjudication was performed.

    Time frame: From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)

  25. Number of Participants With ILD Clinical Symptoms Resolution Among ILD/Pneumonitis Participants Who Have Been Treated With High Dose Steroid

    The number of participants with ILD clinical symptoms resolution in ILD/Pneumonitis participants who have been treated with high dose steroid (\>2 mg dexamethasone) were evaluated.

    Time frame: From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)

07

Results

Posted May 16, 2025

Participant flow

Participants were enrolled in this study from 22 June 2021 (First participant in) and the analyses presented in this results form are based on a final data cut-off of 08 February 2024 and final database lock of 22 April 2024.

Participant flow — Overall Study
MilestoneCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Started241263
Completed3034
Not completed211229
Withdrew: Participant ongoing study at data cutoff date of 08feb24167189
Withdrew: By complete response from the participant10
Withdrew: Lost to follow-up33
Withdrew: Death1313
Withdrew: Participant reports worsening of the general critical condition and will not continue01
Withdrew: Participant is in poor health and will not come to the study site01
Withdrew: Progression confirmed in magnetic resonance imaging01
Withdrew: Adverse event03
Withdrew: Participant decision10
Withdrew: Sub investigator decision approved by medical monitor10
Withdrew: Participant immediately started next line of treatment10
Withdrew: Participant's decision because the treatment makes them anxious10
Withdrew: Lack of clinical benefit10
Withdrew: Disease progression55
Withdrew: Withdrawal by subject1413
Withdrew: Protocol violation10
Withdrew: Physician decision20

Outcome measures

PrimaryObjective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)

The ORR is defined as the percentage (%) of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by independent central review (ICR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

Time frame:
From first dose (Day 1) to progression of disease (up to 2 years 7 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)
Percentage of participantsCohort 1: Trastuzumab Deruxtecan (T-DXd)
Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)62.7 (56.5 to 68.8)
PrimaryProgression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)

The PFS rate is the percentage of participants alive and free of disease progression at 12 months, estimated by the Kaplan-Meier method.

Time frame:
At 12 months
Reported as:
Number · Percentage of participants
Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)
Percentage of participantsCohort 2: Trastuzumab Deruxtecan (T-DXd)
Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)61.6 (54.92 to 67.61)
SecondarySurvival Rate at 12 Months

Survival rate is the percentage of participants alive at 12 months, estimated by the Kaplan-Meier method.

Time frame:
At 12 Months
Reported as:
Number · Percentage of Participants
Survival Rate at 12 Months
Percentage of ParticipantsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Survival Rate at 12 Months90.6 (85.97 to 93.80)90.3 (85.89 to 93.41)
SecondaryObjective Response Rate in Cohort 2 (Participants With Brain Metastasis at Baseline)

The ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.

Time frame:
From first dose (Day 1) to progression of disease (up to 2 years 7 months)
Reported as:
Number · Percentage of participants
Objective Response Rate in Cohort 2 (Participants With Brain Metastasis at Baseline)
Percentage of participantsCohort 2: Trastuzumab Deruxtecan (T-DXd)
Objective Response Rate in Cohort 2 (Participants With Brain Metastasis at Baseline)51.7 (45.7 to 57.8)
SecondaryDuration of Response (DoR)

Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 as assessed by ICR or death due to any cause.

Time frame:
From the date of first documented confirmed response until date of documented progression (up to 2 years 7 months)
Reported as:
Median · Months
Duration of Response (DoR)
MonthsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Duration of Response (DoR)NA (9.5 to NA)NA (8.1 to NA)
SecondaryTime to Progression

Time to progression by RECIST 1.1 per ICR is defined as the time from the date of the first dose of study intervention to the date of documented disease progression.

Time frame:
From first dose (Day 1) to progression of disease (up to 2 years 7 months)
Reported as:
Median · Months
Time to Progression
MonthsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Time to ProgressionNA (NA to NA)NA (NA to NA)
SecondaryDuration of Treatment on Subsequent Lines of Therapy

Duration of treatment on subsequent therapy is defined as the time from the date of first dose of a subsequent therapy until date of the last dose of that therapy.

Time frame:
From the date of first dose of a subsequent therapy until date of last dose of therapy (up to 2 years 7 months)
Reported as:
Median · Months
Duration of Treatment on Subsequent Lines of Therapy
MonthsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
First subsequent line of therapy4.4 (3.3 to 6.3)6.5 (3.9 to 8.8)
First completed subsequent line of therapy3.0 (2.1 to 3.5)3.0 (2.1 to 3.5)
SecondarySecond Progression-Free Survival Rate at 12 Months

Second progression-free survival rate is the percentage of participants alive and free from a second progression on next-line treatment at 12 months, estimated by the Kaplan-Meier method. The second progression is defined as the earliest progression event subsequent to the first anti-cancer therapy after the initial progression.

Time frame:
At 12 Months
Reported as:
Number · Percentage of Participants
Second Progression-Free Survival Rate at 12 Months
Percentage of ParticipantsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Second Progression-Free Survival Rate at 12 Months81.1 (74.85 to 85.92)83.1 (77.46 to 87.44)
SecondaryIncidence of New Symptomatic Central Nervous System (CNS) Metastasis During Treatment Without CNS Metastasis at Baseline (Cohort 1)

The incidence rate is defined as proportion of participants with new symptomatic CNS metastases during treatment period in participants without symptomatic CNS metastasis at baseline.

Time frame:
From first dose (Day 1) to end of treatment (up to 2 years 7 months)
Reported as:
Number · Proportion of participants
Incidence of New Symptomatic Central Nervous System (CNS) Metastasis During Treatment Without CNS Metastasis at Baseline (Cohort 1)
Proportion of participantsCohort 1: Trastuzumab Deruxtecan (T-DXd)
Incidence of New Symptomatic Central Nervous System (CNS) Metastasis During Treatment Without CNS Metastasis at Baseline (Cohort 1)0.017 (0.00452 to 0.04250)
SecondaryTime to Next Progression (CNS or Extracranial) or Death

The time to next progression is defined as the time from the date of the first documented isolated CNS progression to the date of the next documented disease progression (CNS or extracranial) per RECIST 1.1 or death and has been summarized descriptively in participants who have developed isolated CNS progression, receive local therapy, and continue on protocol therapy.

Time frame:
From date of first documented isolated CNS progression to the date of the next documented disease progression (up to 2 years 7 months)
Reported as:
Median · Months
Time to Next Progression (CNS or Extracranial) or Death
MonthsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Time to Next Progression (CNS or Extracranial) or Death3.7 (3.7 to NA)0.2 (0.1 to 0.3)
SecondarySite (CNS vs Extracranial vs Both) of Next Progression

Site of next progression (CNS \[CNS RECIST 1.1\] or extracranial \[systemic RECIST 1.1\] in participants who developed isolated CNS progression, received local therapy, and continued on protocol therapy.

Time frame:
From the date of the first documented isolated CNS progression to the date of the next documented CNS disease progression (up to 2 years 7 months)
Reported as:
Count of participants · Participants
Site (CNS vs Extracranial vs Both) of Next Progression
ParticipantsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
CNS06
Extracranial02
Both04
SecondaryCentral Nervous System Progression-free Survival Rate at 12 Months in Participants With Brain Metastasis at Baseline (Cohort 2)

Central nervous system progression free survival rate is the percentage of participants free from central nervous system progression at 12 months, estimated by the Kaplan-Meier method.

Time frame:
At 12 Months
Reported as:
Number · Percentage of Participants
Central Nervous System Progression-free Survival Rate at 12 Months in Participants With Brain Metastasis at Baseline (Cohort 2)
Percentage of ParticipantsCohort 2: Trastuzumab Deruxtecan (T-DXd)
Central Nervous System Progression-free Survival Rate at 12 Months in Participants With Brain Metastasis at Baseline (Cohort 2)58.9 (51.93 to 65.30)
SecondaryTime to New CNS Lesions in Participants With Brain Metastasis at Baseline (Cohort 2)

The time to new CNS lesions is defined as the time from the date of the first dose of study intervention to the date of documented new CNS lesions by RECIST 1.1 per ICR.

Time frame:
From first dose (Day 1) to the date of documented new CNS lesions (up to 2 years 7 months)
Reported as:
Median · Months
Time to New CNS Lesions in Participants With Brain Metastasis at Baseline (Cohort 2)
MonthsCohort 2: Trastuzumab Deruxtecan (T-DXd)
Time to New CNS Lesions in Participants With Brain Metastasis at Baseline (Cohort 2)NA (NA to NA)
SecondaryCentral Nervous System Objective Response Rate in Participants With Brain Metastasis at Baseline by ICR (Cohort 2)

The CNS ORR is defined as the percentage of participants with measurable brain metastasis at baseline who have a confirmed CR or confirmed PR of brain lesions, as determined by ICR per CNS RECIST 1.1.

Time frame:
From first dose (Day 1) until CNS progression of disease (up to 2 years 7 months)
Reported as:
Number · Percentage of participants
Central Nervous System Objective Response Rate in Participants With Brain Metastasis at Baseline by ICR (Cohort 2)
Percentage of participantsCohort 2: Trastuzumab Deruxtecan (T-DXd)
Central Nervous System Objective Response Rate in Participants With Brain Metastasis at Baseline by ICR (Cohort 2)71.7 (64.2 to 79.3)
SecondaryCentral Nervous System Duration of Response in Participants With Brain Metastasis at Baseline (Cohort 2)

The CNS DoR is defined as the time from the date of first documented confirmed CNS response until date of documented CNS progression per CNS RECIST 1.1 as assessed by ICR or death due to any cause.

Time frame:
From date of first documented confirmed CNS response until CNS progression of disease (up to 2 years 7 months)
Reported as:
Median · Months
Central Nervous System Duration of Response in Participants With Brain Metastasis at Baseline (Cohort 2)
MonthsCohort 2: Trastuzumab Deruxtecan (T-DXd)
Central Nervous System Duration of Response in Participants With Brain Metastasis at Baseline (Cohort 2)NA (6.9 to NA)
SecondaryNumber of Participants With Best on Treatment Visit Response on the European Organization for the Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30)

The EORTC QLQ-C30 is a 30-item questionnaire for cancer assessment. Increased scores indicate improvement; decreased scores indicate deterioration. Physical function: ≥+9= improvement, ≤-10=deterioration, otherwise=no change; Role functioning: ≤-6=deterioration, otherwise=no change; Social functioning: ≥+8=improvement, ≤-7=deterioration, otherwise=no change; Cognitive functioning: ≥+ 5=improvement, ≤- 4=deterioration, otherwise=no change; Global Health Status: ≥+2=improvement, ≤-8=deterioration, otherwise=no change; Fatigue: ≥+8=improvement, ≤-8=deterioration, otherwise=no change; Nausea and vomiting: ≤-11=deterioration, otherwise=no change; Appetite loss: ≤-14=deterioration, otherwise=no change; rest of scales: ≥+10=improvement, ≤-10=deterioration, otherwise=no change. Best on treatment response is best response category (improvement, no change, and deterioration) achieved by participants between first dose and 47 days after last dose, and prior to starting any anticancer therapy.

Time frame:
Time from first dose up to 47 days after last dose, or prior to starting any subsequent therapy, or for up to 2 years 7 months, whichever occurred first
Reported as:
Count of participants · Participants
Number of Participants With Best on Treatment Visit Response on the European Organization for the Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30)
ParticipantsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Appetite loss: Best on-treatment response: Deterioration159
Appetite loss: Best on-treatment response: No change171200
Appetite loss: Best on-treatment response: No follow-up2115
Appetite loss: Best on-treatment response: Missing00
Cognitive Functioning: Best on-treatment response: Deterioration1612
Cognitive Functioning: Best on-treatment response: Improvement5787
Cognitive Functioning: Best on-treatment response: No change116107
Cognitive Functioning: Best on-treatment response: No follow-up1817
Cognitive Functioning: Best on-treatment response: Missing00
Constipation: Best on-treatment response: Deterioration1813
Constipation: Best on-treatment response: Improvement3659
Constipation: Best on-treatment response: No change134139
Constipation: Best on-treatment response: No follow-up1913
Constipation: Best on-treatment response: Missing00
Diarrhoea: Best on-treatment response: Deterioration24
Diarrhoea: Best on-treatment response: Improvement3228
Diarrhoea: Best on-treatment response: No change153174
Diarrhoea: Best on-treatment response: No follow-up2017
Diarrhoea: Best on-treatment response: Missing00
Dyspnea: Best on-treatment response: Deterioration65
Dyspnea: Best on-treatment response: Improvement4849
Dyspnea: Best on-treatment response: No change131154
Dyspnea: Cycle Best on-treatment response: No follow-up2216
Dyspnea: Best on-treatment response: Missing00
Emotional Functioning: Best on-treatment response: Deterioration47
Emotional Functioning: Best on-treatment response: Improvement10998
Emotional Functioning: Best on-treatment response: No change77103
Emotional Functioning: Best on-treatment response: No follow-up1715
Emotional Functioning: Best on-treatment response: Missing00
Fatigue: Best on-treatment response: Deterioration2823
Fatigue: Best on-treatment response: Improvement97119
Fatigue: Best on-treatment response: No change6568
Fatigue: Best on-treatment response: No follow-up1714
Fatigue: Best on-treatment response: Missing00
Financial difficulties: Best on-treatment response: Deterioration79
Financial difficulties: Best on-treatment response: Improvement4658
Financial difficulties: Best on-treatment response: No change135140
Financial difficulties: Best on-treatment response: No follow-up1816
Financial difficulties: Best on-treatment response: Missing00
Global health status / QoL: Best on-treatment response: Deterioration2834
Global health status / QoL: Best on-treatment response: Improvement86111
Global health status / QoL: Best on-treatment response: No change7565
Global health status / QoL: Best on-treatment response: No follow-up1813
Global health status / QoL: Best on-treatment response: Missing00
Insomnia: Best on-treatment response: Deterioration87
Insomnia: Best on-treatment response: Improvement87103
Insomnia: Best on-treatment response: No change9298
Insomnia: Best on-treatment response: No follow-up2016
Insomnia: Best on-treatment response: Missing00
Nausea and vomiting: Best on-treatment response: Deterioration179
Nausea and vomiting: Best on-treatment response: No change167201
Nausea and vomiting: Best on-treatment response: No follow-up2314
Nausea and vomiting: Best on-treatment response: Missing00
Pain: Best on-treatment response: Deterioration48
Pain: Best on-treatment response: Improvement91115
Pain: Best on-treatment response: No change9489
Pain: Best on-treatment response: No follow-up1812
Pain: Best on-treatment response: Missing00
Physical Functioning: Best on-treatment response: Deterioration1013
Physical Functioning: Best on-treatment response: Improvement5471
Physical Functioning: Best on-treatment response: No change122124
Physical Functioning: Best on-treatment response: No follow-up2116
Physical Functioning: Best on-treatment response: Missing00
Role Functioning: Best on-treatment response: Deterioration2015
Role Functioning: Best on-treatment response: No change167197
Role Functioning: Best on-treatment response: No follow-up2012
Role Functioning: Best on-treatment response: Missing00
Social Functioning: Best on-treatment response: Deterioration1916
Social Functioning: Best on-treatment response: Improvement81109
Social Functioning: Best on-treatment response: No change8783
Social Functioning: Best on-treatment response: No follow-up2015
Social Functioning: Best on-treatment response: Missing00
SecondaryNumber of Participants With Neurologic Assessment in Neuro-Oncology Scale (NANO Scale)

The NANO scale is a clinician-reported assessment of neurologic functioning in neuro-oncology participants. The instrument captures 9 domains (gait, strength, ataxia, sensation, visual fields, facial strength, language, level of consciousness, and behavior) and was developed to provide a simple, objective assessment of neurologic function that would be combined with radiographic assessment to provide an overall outcome assessment for neuro-oncology participants in clinical trials and in daily practice. The soring scale for Gait consists of score range 0-3, Strength consists of score range 0-2, ataxia (upper extremity) consists of scale range 0-2 and sensation as 0. Higher scores indicate worse neurologic function. The response categories reported are changes from first post-baseline score to worst on-treatment score at any point of treatment.

Time frame:
Time from first dose up to 47 days after last dose, or prior to starting any subsequent therapy, or for up to 2 years 7 months, whichever occurred first
Reported as:
Count of participants · Participants
Number of Participants With Neurologic Assessment in Neuro-Oncology Scale (NANO Scale)
ParticipantsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Neurologic response34
Neurologic stability217220
Neurologic progression1625
Not assessed05
Non-evaluable00
SecondaryCognitive Functions Tests: Paired Associates Learning (PAL) First Attempt Memory Score (PALFAMS)

The PAL is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included PAL and was a low-burden, highly sensitive, precise measure of cognitive function. The PALFAMS is the number of times a participant chose the correct box on their first attempt when recalling the pattern locations, calculated across all assessed trials. A higher number of events of selecting correct boxes indicates better cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

Time frame:
Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Reported as:
Mean · Number of Events
Cognitive Functions Tests: Paired Associates Learning (PAL) First Attempt Memory Score (PALFAMS)
Number of EventsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Paired Assistance Learning (PAL) first attempt Memory score: Baseline10.9 ± 4.6310.4 ± 4.71
PAL first attempt Memory score: Cycle 5 Day 111.7 ± 4.8110.8 ± 4.48
PAL first attempt Memory score: Cycle 9 Day 112.5 ± 4.3611.4 ± 4.59
PAL first attempt Memory score: Cycle 13 Day 112.4 ± 4.8611.8 ± 4.56
PAL first attempt Memory score: Cycle 17 Day 113.2 ± 4.6112.2 ± 5.07
SecondaryCognitive Functions Tests: Paired Associates Learning Total Errors Adjusted (PALTEA)

The PAL is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included PALTEA and was a low-burden, highly sensitive, precise measure of cognitive function. PALTEA is the number of times a participant chose the incorrect box for a stimulus on assessment problems, plus an adjustment for the estimated number of errors they would have made on any problems, attempts, and recalls they did not reach. A higher number of events of selecting incorrect boxes indicates worse cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

Time frame:
Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Reported as:
Mean · Number of Events
Cognitive Functions Tests: Paired Associates Learning Total Errors Adjusted (PALTEA)
Number of EventsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
PAL Total Errors (Adjusted): Baseline21.8 ± 17.1824.8 ± 17.59
PAL Total Errors (Adjusted): Cycle 5 Day 119.2 ± 16.4723.1 ± 17.53
PAL Total Errors (Adjusted): Cycle 9 Day 117.2 ± 15.1721.5 ± 17.32
PAL Total Errors (Adjusted): Cycle 13 Day 117.5 ± 16.3319.2 ± 16.31
PAL Total Errors (Adjusted): Cycle 17 Day 115.0 ± 14.9219.2 ± 17.66
SecondaryCognitive Functions Tests: Reaction Time (RTI)

This is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included Reaction Time Task (RTI) and was low-burden, highly sensitive, precise measures of cognitive function. RTI Median Five-Choice Movement Time: median time taken for a participant to release response button and select target stimulus after it flashed yellow on screen. Calculated across correct, assessed trials in which stimulus could appear in any one of five locations. RTI Median Five-Choice Reaction Time: median duration it took for a participant to release response button after presentation of target stimulus. Calculated across correct, assessed trials in which stimulus could appear in any one of five locations. Measured in milliseconds. Higher reaction times indicate worse cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

Time frame:
Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Reported as:
Mean · Millisecond (msec)
Cognitive Functions Tests: Reaction Time (RTI)
Millisecond (msec)Cohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Reaction time (RTI) Median Five-Choice Movement Time: Baseline314.7 ± 117.03329.4 ± 141.24
RTI Median Five-Choice Movement Time: Cycle 5 Day 1309.1 ± 94.85310.5 ± 110.94
RTI Median Five-Choice Movement Time: Cycle 9 Day 1305.3 ± 93.47326.7 ± 106.02
RTI Median Five-Choice Movement Time: Cycle 13 Day 1308.4 ± 89.55324.1 ± 115.24
RTI Median Five-Choice Movement Time: Cycle 17 Day 1319.6 ± 151.42316.4 ± 96.69
RTI Median Five-Choice Reaction Time: Baseline401.3 ± 70.63423.6 ± 115.56
RTI Median Five-Choice Reaction Time: Cycle 5 Day 1408.7 ± 119.26413.0 ± 84.25
RTI Median Five-Choice Reaction Time: Cycle 9 Day 1401.5 ± 73.18414.5 ± 67.68
RTI Median Five-Choice Reaction Time: Cycle 13 Day 1401.0 ± 63.56412.3 ± 77.07
RTI Median Five-Choice Reaction Time: Cycle 17 Day 1396.8 ± 81.63402.8 ± 51.93
SecondaryCognitive Functions Tests: Spatial Working Memory (SWM)

The SWM is a computerized cognitive test. The SWM Between Errors (SWMBE) is number of times a participant incorrectly revisits a box in which a token has previously been found, calculated across all 4, 6, and 8 token trials. SWM Between Errors 4 Boxes (SWMBE4), SWM Between Errors 6 Boxes (SWMBE6), and SWM Between Errors 8 Boxes (SWMBE8) are number of times a participant revisits a box in which a token has previously been found. These are calculated across all trials with 4 tokens only for SWMBE4, 6 tokens only for SWMBE6, and 8 tokens only for SWMBE8. SWM Total Errors is number of times a box is selected that is certain not to contain a token and therefore should not have been visited by participant. A higher number of incorrect revisit events to previously found token boxes indicates worse cognitive function, and a lower number of revisit events indicates better cognitive function. Here, baseline was last non-missing value prior to administration of first dose of study intervention.

Time frame:
Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Reported as:
Mean · Number of Events
Cognitive Functions Tests: Spatial Working Memory (SWM)
Number of EventsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Spatial working memory (SWM) Between Errors: Baseline17.2 ± 8.8918.6 ± 8.69
SWM Between Errors: Cycle 5 Day 115.5 ± 10.1116.8 ± 8.39
SWM Between Errors: Cycle 9 Day 115.1 ± 9.7816.3 ± 9.22
SWM Between Errors: Cycle 13 Day 113.4 ± 9.5615.0 ± 8.85
SWM Between Errors: Cycle 17 Day 113.5 ± 9.4813.7 ± 9.50
SWM Between Errors 4 Boxes: Baseline1.4 ± 1.391.4 ± 1.46
SWM Between Errors 4 Boxes: Cycle 5 Day 11.0 ± 1.391.1 ± 1.42
SWM Between Errors 4 Boxes: Cycle 9 Day 10.9 ± 1.331.1 ± 1.42
SWM Between Errors 4 Boxes: Cycle 13 Day 10.8 ± 1.230.9 ± 1.37
SWM Between Errors 4 Boxes: Cycle 17 Day 10.9 ± 1.320.7 ± 1.17
SWM Between Errors 6 Boxes: Baseline5.0 ± 3.445.2 ± 3.53
SWM Between Errors 6 Boxes: Cycle 5 Day 14.3 ± 3.414.6 ± 3.42
SWM Between Errors 6 Boxes: Cycle 9 Day 14.2 ± 3.644.7 ± 3.84
SWM Between Errors 6 Boxes: Cycle 13 Day 13.2 ± 3.384.1 ± 3.34
SWM Between Errors 6 Boxes: Cycle 17 Day 13.7 ± 3.254.0 ± 3.51
SWM Between Errors 8 Boxes: Baseline10.9 ± 5.6612.1 ± 5.45
SWM Between Errors 8 Boxes: Cycle 5 Day 110.2 ± 6.6111.2 ± 5.31
SWM Between Errors 8 Boxes: Cycle 9 Day 110.0 ± 6.3110.5 ± 5.52
SWM Between Errors 8 Boxes: Cycle 13 Day 19.3 ± 6.279.9 ± 5.91
SWM Between Errors 8 Boxes: Cycle 17 Day 18.9 ± 6.429.0 ± 6.33
SWM Total Errors: Baseline17.5 ± 8.9619.0 ± 8.75
SWM Total Errors: Cycle 5 Day 115.9 ± 10.2417.3 ± 8.59
SWM Total Errors: Cycle 9 Day 115.5 ± 9.8916.7 ± 9.42
SWM Total Errors: Cycle 13 Day 113.7 ± 9.7115.3 ± 8.91
SWM Total Errors: Cycle 17 Day 113.8 ± 9.6313.9 ± 9.63
SecondaryCognitive Functions Tests: Spatial Working Memory Strategy (SWMS)

The SWM is a computerized cognitive test. The SWMS, the number of times a participant restarted search patterns from the same initial box, indicating their use of a planned strategy to find tokens. An increased number of events where search patterns started from the same initial box suggested participants were using a planned strategy to find tokens, which indicated better cognitive function. Here, a low score indicated high strategy use (1 = they always began the search from the same box). Conversely, high scores represented a decrease in events of beginning searches from the same box. Instead, starting from many different boxes suggested the participant was not using a consistent strategy, which indicated worse cognitive function. This was calculated across assessed trials with 6 tokens or more. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

Time frame:
Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Reported as:
Mean · Number of Events
Cognitive Functions Tests: Spatial Working Memory Strategy (SWMS)
Number of EventsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
SWM Strategy (6-8 Boxes): Baseline8.8 ± 2.309.1 ± 2.32
SWM Strategy (6-8 Boxes): Cycle 5 Day 18.4 ± 2.808.8 ± 2.42
SWM Strategy (6-8 Boxes): Cycle 9 Day 18.2 ± 2.708.5 ± 2.44
SWM Strategy (6-8 Boxes): Cycle 13 Day 17.9 ± 3.188.6 ± 2.79
SWM Strategy (6-8 Boxes): Cycle 17 Day 17.9 ± 3.138.0 ± 3.08
SecondarySt. George's Respiratory Questionnaire - Idiopathic (SGRQ-I) Pulmonary Fibrosis Version in Participants With Interstitial Lung Disease (ILD)/Pneumonitis

The effect of T-DXd on symptoms, functioning, and HRQoL in HER2+ MBC participants with or without baseline brain metastasis was evaluated. The SGRQ-I is an idiopathic pulmonary fibrosis-specific version of the instrument developed and validated for use among participants with idiopathic pulmonary fibrosis, a type of ILD. The SGRQ-I was used to assess the HRQoL among participants who have been diagnosed with ILD/pneumonitis. It includes 34 of the original SGRQ items determined to be most reliable for assessing the HRQoL of participants with idiopathic pulmonary fibrosis. The instrument yields 3 domain scores (symptoms, activity, and impact) as well as a total score, with scores ranging from 0 to 100. Higher scores indicate greater impairment in HRQoL.

Time frame:
From time of ILD/pneumonitis diagnosis (every week) until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)
Reported as:
Mean · Score on scale
St. George's Respiratory Questionnaire - Idiopathic (SGRQ-I) Pulmonary Fibrosis Version in Participants With Interstitial Lung Disease (ILD)/Pneumonitis
Score on scaleCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Total: Baseline32.1 ± 19.3127.6 ± 20.97
Total: Week 128.2 ± 17.1033.1 ± 30.33
Total: Week 223.3 ± 22.9121.5 ± 14.48
Total: Week 319.5 ± 20.1015.3 ± 15.23
Total: Week 44.2 ± 1.0917.8 ± 15.49
Total: Week 58.0 ± 6.4015.9 ± 15.43
Total: Week 66.7 ± 2.3916.4 ± 11.95
Total: Week 75.4 ± 3.4914.8 ± 15.73
Total: Week 83.3 ± 1.7516.9 ± 17.04
Total: Week 98.0 ± 4.2923.3 ± 17.20
Total: Week 106.6 ± 2.3618.6 ± 14.54
Total: Week 118.9 ± 1.7920.3 ± 14.92
Total: Week 128.4 ± 2.7321.8 ± 14.40
Total: Week 136.2 ± 0.2720.4 ± 17.95
Total: Week 145.5 ± 2.978.6 ± 7.19
Total: Week 154.2 ± 1.0912.9 ± 10.49
Total: Week 164.2 ± 1.0912.3 ± 10.10
Total: Week 174.2 ± 1.0912.1 ± 15.07
Total: Week 184.2 ± 1.0913.3 ± 16.29
Total: Week 199.1 ± 7.028.7 ± 9.07
Total: Week 207.9 ± 6.416.2 ± 3.86
Total: Week 217.5 ± 5.785.2 ± 2.58
Total: Week 226.7 ± 2.4415.4 ± 13.24
Total: Week 236.7 ± 2.449.8 ± 9.74
Total: Week 246.7 ± 2.4417.3 ± 15.09
Total: Week 255.6 ± 2.5611.0 ± 10.90
Total: Week 265.6 ± 2.5610.5 ± 10.81
Total: Week 275.6 ± 2.5613.5 ± 11.53
Total: Week 285.6 ± 2.5610.7 ± 11.13
Total: Week 296.7 ± 2.4416.5 ± 16.52
Total: Week 304.7 ± 1.1919.6 ± 18.60
Total: Week 315.6 ± 2.5615.9 ± 13.98
Total: Week 325.6 ± 2.5611.4 ± 10.89
Total: Week 336.7 ± 2.445.2 ± 3.15
Total: Week 345.5 ± 2.6211.9 ± 10.36
Total: Week 356.6 ± 2.7611.9 ± 10.32
Total: Week 366.7 ± 2.4415.9 ± 17.62
Total: Week 375.4 ± 2.4511.5 ± 9.72
Total: Week 386.7 ± 2.4411.8 ± 10.13
Total: Week 395.0 ± NA6.2 ± 3.86
Total: Week 405.6 ± 2.566.2 ± 3.86
Total: Week 415.6 ± 2.568.9 ± NA
Total: Week 426.7 ± 2.446.2 ± 3.86
Total: Week 435.6 ± 2.566.2 ± 3.86
Total: Week 447.4 ± 5.546.2 ± 3.86
Total: Week 459.5 ± NA6.2 ± 3.86
Total: Week 466.7 ± 2.448.9 ± NA
Total: Week 476.7 ± 2.446.2 ± 3.86
Total: Week 486.7 ± 2.446.2 ± 3.86
Total: Week 496.7 ± 2.448.9 ± NA
Total: Week 509.1 ± 0.996.2 ± 3.86
Total: Week 518.2 ± 0.3210.4 ± NA
Total: Week 526.7 ± 2.44—
Total: Week 536.7 ± 2.448.9 ± NA
Total: Week 546.7 ± 2.448.9 ± NA
Total: Week 556.7 ± 2.448.9 ± NA
Total: Week 567.5 ± 3.538.9 ± NA
Total: Week 578.4 ± NA8.9 ± NA
Total: Week 588.4 ± NA8.9 ± NA
Total: Week 5910.0 ± NA8.9 ± NA
Total: Week 608.4 ± NA8.9 ± NA
Total: Week 618.4 ± NA8.9 ± NA
Total: Week 628.4 ± NA8.9 ± NA
Total: Week 6310.0 ± NA8.9 ± NA
Total: Week 648.4 ± NA8.9 ± NA
Total: Week 65—8.9 ± NA
Total: Week 66—8.9 ± NA
Total: Week 67—8.9 ± NA
Total: Week 68—8.9 ± NA
Total: Week 69—8.9 ± NA
Total: Week 70—8.9 ± NA
Total: Week 71—8.9 ± NA
Total: Week 72—8.9 ± NA
End of treatment31.1 ± 18.6518.0 ± 19.16
Safety Follow-up23.4 ± 6.3821.4 ± 25.36
SecondaryMD Anderson Symptom Inventory Brain Tumor-Specific Items in Brain Metastasis at Baseline Participants

The T-DXd on symptoms, functioning, and HRQoL in HER2+ MBC participants with or without baseline brain metastasis was evaluated. The MDASI brain tumor module includes 9 symptoms specific to brain tumors (weakness on one side of the body, difficulty understanding, difficulty speaking, seizures, difficulty concentrating, problems with vision, change in appearance, change in bowel pattern (diarrhea or constipation), and irritability). These 9 items will be used to capture symptoms associated with brain metastasis for those diagnosed with brain metastasis. Each item is rated on an 11-point numeric rating scale on a scale of 0-10, with higher scores indicating greater symptom severity. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, and Cycle 39 Day 1 (21 days cycle)
Reported as:
Mean · Score on scale
MD Anderson Symptom Inventory Brain Tumor-Specific Items in Brain Metastasis at Baseline Participants
Score on scaleCohort 2: Trastuzumab Deruxtecan (T-DXd)
Change in Appearance at Its Worst: Baseline1.8 ± 2.44
Change in Appearance at Its Worst: Cycle 2 Day 11.9 ± 2.44
Change in Appearance at Its Worst: Cycle 3 Day 12.1 ± 2.51
Change in Appearance at Its Worst: Cycle 4 Day 11.9 ± 2.20
Change in Appearance at Its Worst: Cycle 5 Day 12.1 ± 2.45
Change in Appearance at Its Worst: Cycle 39 Day 13.0 ± NA
Change in Bowel Pattern at Its Worst: Baseline1.7 ± 2.46
Change in Bowel Pattern at Its Worst: Cycle 2 Day 12.5 ± 2.55
Change in Bowel Pattern at Its Worst: Cycle 3 Day 12.7 ± 2.67
Change in Bowel Pattern at Its Worst: Cycle 4 Day 13.0 ± 2.74
Change in Bowel Pattern at Its Worst: Cycle 5 Day 12.8 ± 2.69
Change in Bowel Pattern at Its Worst: Cycle 39 Day 10 ± NA
Difficulty Concentrating at Its Worst: Baseline1.8 ± 2.23
Difficulty Concentrating at Its Worst: Cycle 2 Day 11.7 ± 2.03
Difficulty Concentrating at Its Worst: Cycle 3 Day 11.9 ± 2.27
Difficulty Concentrating at Its Worst: Cycle 4 Day 11.6 ± 2.03
Difficulty Concentrating at Its Worst: Cycle 5 Day 11.5 ± 1.95
Difficulty Concentrating at Its Worst: Cycle 39 Day 11.0 ± NA
Difficulty Speaking at Its Worst: Baseline1.4 ± 2.18
Difficulty Speaking at Its Worst: Cycle 2 Day 11.3 ± 1.96
Difficulty Speaking at Its Worst: Cycle 3 Day 11.4 ± 1.97
Difficulty Speaking at Its Worst: Cycle 4 Day 11.1 ± 1.80
Difficulty Speaking at Its Worst: Cycle 5 Day 11.3 ± 1.98
Difficulty Speaking at Its Worst: Cycle 39 Day 11.0 ± NA
Difficulty Understanding at Its Worst: Baseline1.5 ± 2.29
Difficulty Understanding at Its Worst: Cycle 2 Day 10.9 ± 1.67
Difficulty Understanding at Its Worst: Cycle 3 Day 11.2 ± 1.87
Difficulty Understanding at Its Worst: Cycle 4 Day 11.0 ± 1.83
Difficulty Understanding at Its Worst: Cycle 5 Day 10.9 ± 1.68
Difficulty Understanding at Its Worst: Cycle 39 Day 10 ± NA
Irritability at its Worst: Baseline1.8 ± 2.27
Irritability at its Worst: Cycle 2 Day 11.9 ± 2.23
Irritability at its Worst: Cycle 3 Day 11.8 ± 2.04
Irritability at its Worst: Cycle 4 Day 11.9 ± 2.06
Irritability at its Worst: Cycle 5 Day 11.9 ± 2.12
Irritability at its Worst: Cycle 39 Day 14.0 ± NA
Seizures at Its Worst: Baseline0.5 ± 1.58
Seizures at Its Worst: Cycle 2 Day 10.5 ± 1.38
Seizures at Its Worst: Cycle 3 Day 10.5 ± 1.52
Seizures at Its Worst: Cycle 4 Day 10.5 ± 1.47
Seizures at Its Worst: Cycle 5 Day 10.5 ± 1.40
Seizures at Its Worst: Cycle 39 Day 10 ± NA
Vision at Its Worst: Baseline1.6 ± 2.28
Vision at Its Worst: Cycle 2 Day 11.6 ± 2.24
Vision at Its Worst: Cycle 3 Day 11.5 ± 2.10
Vision at Its Worst: Cycle 4 Day 11.4 ± 1.94
Vision at Its Worst: Cycle 5 Day 11.5 ± 2.01
Vision at Its Worst: Cycle 39 Day 11.0 ± NA
Weakness on One Body Side at Its Worst: Baseline2.1 ± 2.54
Weakness on One Body Side at Its Worst: Cycle 2 Day 11.7 ± 2.35
Weakness on One Body Side at Its Worst: Cycle 3 Day 11.8 ± 2.28
Weakness on One Body Side at Its Worst: Cycle 4 Day 11.8 ± 2.48
Weakness on One Body Side at Its Worst: Cycle 5 Day 11.6 ± 2.18
Weakness on One Body Side at Its Worst: Cycle 39 Day 10 ± NA
SecondaryNumber of Participants With Adverse Events (AEs)

The safety and tolerability of the participants who received T-DXd was evaluated. SAE=Serious adverse events; CTCAE=Common Terminology for Adverse Events

Time frame:
From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Any AE237259
Any AE, excluding AEs associated with COVID-19237259
Any AE associated with COVID-194554
Any AE possibly related to treatment230242
Any AE of CTCAE grade 3 or higher118134
Any AE of CTCAE grade 3 or higher, possibly related to treatment98100
Any AE with outcome = death68
Any AE with outcome = death, excluding AEs associated with COVID-1968
Any AE with outcome = death, associated with COVID-1900
Any AE with outcome = death, possibly related to treatment56
Any SAE (events with outcome = death)4662
Any SAE (events with outcome = death), possibly related to treatment2525
Any AE leading to dose reduction6560
Any AE leading to dose reduction, possibly related to treatment6353
Any AE leading to dose interruption124146
Any AE leading to dose interruption, possibly related to treatment8283
Any AE leading to discontinuation of treatment2340
Any AE leading to discontinuation of treatment, excluding AEs associated with COVID-192339
Any AE leading to discontinuation of treatment, associated with COVID-1901
Any AE leading to discontinuation of treatment, possibly related to treatment2034
Any SAE leading to discontinuation of treatment818
Any SAE leading to discontinuation of treatment, possibly related to treatment613
Any Other Adverse events (OAE)05
Any Adverse event of special event5471
SecondaryNumber of Participants With Investigator-assessed ILD/Pneumonitis

The number of participants with ILD/Pneumonitis were by grouped term based on Investigator-reported preferred terms. No adjudication was performed.

Time frame:
From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)
Reported as:
Count of participants · Participants
Number of Participants With Investigator-assessed ILD/Pneumonitis
ParticipantsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Interstitial lung disease1917
Lung opacity20
Pneumonitis1024
Pulmonary fibrosis11
Radiation pneumonitis10
Lung infiltration01
SecondaryNumber of Participants With ILD Clinical Symptoms Resolution Among ILD/Pneumonitis Participants Who Have Been Treated With High Dose Steroid

The number of participants with ILD clinical symptoms resolution in ILD/Pneumonitis participants who have been treated with high dose steroid (\>2 mg dexamethasone) were evaluated.

Time frame:
From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)
Reported as:
Count of participants · Participants
Number of Participants With ILD Clinical Symptoms Resolution Among ILD/Pneumonitis Participants Who Have Been Treated With High Dose Steroid
ParticipantsCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
Resolved: Recovered/resolved1824
Resolved: Recovering/resolving12
Resolved: Recovered/resolved with sequelae11
Unresolved: Not recovered/resolved66
Unresolved: Fatal36

Adverse events

Collected over From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Trastuzumab Deruxtecan (T-DXd)41/241 (17%)46/241 (19.1%)235/241 (97.5%)
Cohort 2: Trastuzumab Deruxtecan (T-DXd)43/263 (16.3%)62/263 (23.6%)253/263 (96.2%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
PneumoniaInfections and infestations7/2413/263
PneumonitisRespiratory, thoracic and mediastinal disorders4/2417/263
NauseaGastrointestinal disorders3/2416/263
HypokalaemiaMetabolism and nutrition disorders5/2410/263
AnaemiaBlood and lymphatic system disorders3/2415/263
SeizureNervous system disorders0/2415/263
VomitingGastrointestinal disorders4/2411/263
EpilepsyNervous system disorders1/2414/263
COVID-19Infections and infestations3/2410/263
HeadacheNervous system disorders0/2413/263
Most frequent other events
Showing 10 of 49
Most frequent other events
EventCohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)
NauseaGastrointestinal disorders171/241168/263
AstheniaGeneral disorders103/24171/263
ConstipationGastrointestinal disorders98/241105/263
FatigueGeneral disorders77/24195/263
DiarrhoeaGastrointestinal disorders85/24174/263
AlopeciaSkin and subcutaneous tissue disorders83/24175/263
VomitingGastrointestinal disorders80/24173/263
NeutropeniaBlood and lymphatic system disorders63/24158/263
AnaemiaBlood and lymphatic system disorders62/24167/263
HeadacheNervous system disorders48/24155/263

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)Total
Mean54.8 ± 11.952.8 ± 11.253.8 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)Total
Female241263504
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)Total
Asian151934
Black or African American246
White209231440
Other13619
Not reported112
Missing123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Trastuzumab Deruxtecan (T-DXd)Cohort 2: Trastuzumab Deruxtecan (T-DXd)Total
Hispanic or Latino201535
Not Hispanic or Latino219245464
Missing235
08

Study locations

81 sites
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Auchenflower, 4066, Australia
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Subiaco, 6008, Australia
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Vancouver, British Columbia V5Z 1H7, Canada
  • Research Site
    Toronto, Ontario M4N 3M5, Canada
  • Research Site
    Copenhagen, 2100, Denmark
  • Research Site
    Herlev, 2730, Denmark
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Helsinki, 00290, Finland
  • Research Site
    Tampere, FI-33521, Finland
  • Research Site
    Turku, 20520, Finland
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Dresden, 1307, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45136, Germany
  • Research Site
    Frankfurt, 60389, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Mannheim, 68167, Germany
  • Research Site
    München, 80336, Germany
  • Research Site
    München, 80637, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Cork, T12 DV56, Ireland
  • Research Site
    Dublin, 7, Ireland
  • Research Site
    Dublin, D04 Y8V0, Ireland
  • Research Site
    Ancona, 60122, Italy
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Catania, 95126, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Prato, 59100, Italy
  • Research Site
    Isehara, 259-1193, Japan
  • Research Site
    Kawasaki-shi, 216-8511, Japan
  • Research Site
    Sapporo, 003-0804, Japan
  • Research Site
    Shinagawa-ku, 142-8666, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Maastricht, 6229 HX, Netherlands
  • Research Site
    The Hague, 2545 AA, Netherlands
  • Research Site
    Bergen, 5009, Norway
  • Research Site
    Oslo, 450, Norway
  • Research Site
    Oslo, N-0379, Norway
  • Research Site
    Gdansk, 80-214, Poland
  • Research Site
    Krakow, 31-501, Poland
  • Research Site
    Opole, 45-060, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Warsaw, 04-141, Poland
  • Research Site
    Lisbon, 1400-048, Portugal
  • Research Site
    Lisbon, 1649-035, Portugal
  • Research Site
    Porto, 4099-001, Portugal
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Bilbao (Vizcaya), 48013, Spain
  • Research Site
    Granada, 18014, Spain
  • Research Site
    Madrid, 28005, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Salamanca, 37007, Spain
  • Research Site
    Santander, 39008, Spain
  • Research Site
    Santiago de Compostela-Coruña, 15706, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Valencia, 46009, Spain
  • Research Site
    Gothenburg, 413 45, Sweden
  • Research Site
    Lund, 221 85, Sweden
  • Research Site
    Uppsala, 751 85, Sweden
  • Research Site
    Basel, 4031, Switzerland
  • Research Site
    Bellinzona, CH-6500, Switzerland
  • Research Site
    Lausanne, 1011, Switzerland
  • Research Site
    Lucerne, 6000, Switzerland
  • Research Site
    Edinburgh, EH4 2XR, United Kingdom
09

References and documents

Publications

  • Harbeck N, Ciruelos E, Jerusalem G, Muller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gion M, Guarneri V, Bianchini G, Wildiers H, Escriva-de-Romani S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13. PubMed 39271844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Feb 2024, 31 months.

Results were first posted in May 2025, 1 year 3 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 31 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2021
First posted
Feb 5, 2021
StartActual
Jun 22, 2021
Primary completionActual
Feb 8, 2024
CompletionEst.
May 26, 2027
Results first posted
May 16, 2025
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04739761
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Jun 22, 2021
Primary completion
Feb 8, 2024
Completion
May 26, 2027 (estimated)
Results posted
May 16, 2025
Last update
Nov 12, 2026

Study contacts

Nadia Harbeck, MD, PhD
principal investigator · Head, Breast Center, Ludwig-Maximilians-University of Munich Department of Obstetrics and Gynecology Marchioninistr. 15, 81377 Munich, Germany
Nancy U. Lin, MD
principal investigator · Associate Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers Director, Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion